Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.58 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.51 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.45 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110741 | 0.84 | DRD2 (0.54) | DRD2ADRA1DADRA1AADRA1BSSTR1 | |
| SCHEMBL5102068 | 0.83 | DRD2 (0.54) | DRD2ADRA1DADRA1AADRA1BOPRM1 | |
| SCHEMBL5111970 | 0.79 | DRD2 (0.59) | DRD2ADRA1DADRA1AADRA1BSSTR1 | |
| SCHEMBL5104743 | 0.79 | SSTR1 (0.48) | DRD2ADRA1DADRA1AADRA1BSSTR1 | |
| SCHEMBL13999223 | 0.78 | KDM1A (0.58) | DRD2OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL5097593 | 0.77 | DRD2 (0.56) | DRD2ADRA1DADRA1AADRA1BSSTR1 | |
| SCHEMBL5102082 | 0.77 | DRD2 (0.58) | DRD2ADRA1DADRA1AADRA1BCHRM4 | |
| SCHEMBL5110473 | 0.74 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL5102071 | 0.74 | DRD2 (1.00) | DRD2ADRA1DADRA1AADRA1B | |
| SCHEMBL31333337 | 0.74 | OPRM1 (0.42) | DRD2SLC2A1CCRL2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| US-7470711-B2 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-30 | — | — | US | disclosed |
| EP-1865956-A2 | PIPERIDINYL SUBSTITUTED CYCLOHEXANE-1,4-DIAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006101859-A2 | PIPERIDINYL SUBSTITUTED CYCLOHEXANE-1,4-DIAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217419-A1 | Piperidinyl substituted cyclohexane-1,4-diamines | ADRA1D, ADRA1A, ADRB1 | DRD2 98/4885ADRA1D 1/4885ADRA1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.